Aims: To investigate further the finding that insulin enhances brain glucose uptake (BGU) in obese but not in lean people by combining BGU with measures of endogenous glucose production (EGP), and to explore the associations between insulin-stimulated BGU and peripheral markers, such as metabolites and inflammatory markers.
| INTRODUCTION
Brain glucose metabolism has long been considered not to be influenced by insulin, but this view has recently been challenged. 1, 2 Insulin receptors are found throughout the human brain, with especially high concentrations in the hypothalamus, cerebellum and cortex. 3 Although the peripheral effects of insulin are well known, the central effects of insulin on the human brain remain poorly understood.
Moreover, whether insulin action in the brain can affect peripheral glucose metabolism, namely, glucose production and utilization, has not been extensively assessed in humans. A connection between brain and endogenous glucose production (EGP) is of special interest as deregulation of insulin-induced EGP suppression is a characteristic of type 2 diabetes (T2D) that contributes to fasting hyperglycaemia. 4 In an early animal study, activation of the ventromedial nucleus of the hypothalamus was found to increase plasma glucose levels by accelerating glycogenolysis in the liver, suggesting that the hypothalamus could directly control EGP. 5 Later work in rats showed that administration of insulin agonists directly into the third cerebral ventricle suppresses EGP. 6 This effect was thought to operate through the phosphatidylinositol-3-kinase pathway as it was abolished by administration of K ATP inhibitors. 6 Moreover, insulin in the brain activates the hepatic signal transducer and activator of transcription 3 (STAT3) in a process involving interleukin-6 (IL-6), as demonstrated by the fact that disturbing IL-6 signalling abolished insulin-induced phosphorylation of hepatic STAT3
and attenuated EGP suppression. 7 Several lines of research have provided evidence that central glucose sensing, involving glucose-regulated neurons as well as astrocytes, may also modulate EGP. 8 Recent findings on brain insulin action in larger animals and humans support the existence of a "brain-liver axis". Although insulin administration into the head arteries of dogs did not suppress hepatic glucose production, hepatic glycogen synthesis was increased and mRNA expression of gluconeogenic enzymes was decreased. 9 In a small study in humans, Dash et al. 10 showed that intranasal insulin administration suppresses EGP during a pancreatic clamp. In addition, Heni et al. 11 have recently demonstrated that intranasal insulin application decreases EGP in lean but not in overweight subjects.
We previously showed that insulin stimulation enhances brain glu- ; therefore, we hypothesized that the two variables (ie, BGU and EGP) might be interrelated in morbidly obese individuals. The aim of the present study was to test whether BGU was associated with EGP in humans. Moreover, possible associations between insulin-stimulated BGU and peripheral markers such as metabolites and inflammatory markers were also explored.
| MATERIALS AND METHODS

| Study population
This study follows up on a previous study, the rationale and methodology of which have been published. 13, 15, 16 In brief, 20 morbidly obese individuals were recruited as part of a larger randomized, controlled clinical study comparing laparoscopic sleeve gastrectomy (n = 9) with
Roux-en-Y gastric bypass (RYGB, n = 11) in the treatment of morbid obesity (the SLEEVEPASS study, NCT00793143). 16 Individuals with T2D used only metformin (1-3 g daily); those on insulin treatment were excluded from the study. Other inclusion criteria have been previously described. 16 Twelve healthy, lean control individuals were recruited via an advertisement in local newspapers.
| Study design
All participants underwent a screening visit before inclusion in the study. At the visit, an oral glucose tolerance test (OGTT) was performed, with blood samples drawn before and at 30, 60, 90 and 120 minutes for glucose, insulin and C-peptide measurements. Fasting blood samples for metabolomics were also collected. At baseline, magnetic resonance imaging (MRI) and two 18 F-FDG PET studies, the first in the fasting state and the second during euglycaemic hyperinsulinaemia, were performed and both these measurements were repeated 6 months after bariatric surgery. 17 The PET studies were performed on separate days, <2 weeks apart. Baseline studies were carried out before the obese participants started a 4-week very-low-energy dietary regime prior to the surgery. A total of 17 participants completed the studies after surgery, because three did not return for the postsurgery studies for personal reasons. In one participant, steady-state was not achieved during the euglycaemic clamp and her study was therefore excluded from the analysis (laparoscopic sleeve gastrectomy, n = 8; RYGB, n = 8). Healthy participants were studied once. 
| PET study protocol and data acquisition
The studies were performed after a 12-hour fast using the GE Advance PET camera (General Electric Medical Systems, Milwaukee, Wisconsin). The euglycaemic hyperinsulinaemic clamp technique was applied as previously described. 18 In brief, in all 20 obese and 12 lean participants a primed-continuous insulin infusion (at a rate of 40 mU/ m 2 /min) was started and continued until the end of the study F-FDG (187 AE 9 MBq) was injected intravenously over 15 seconds, and radioactivity in the brain was followed thereafter for 40 minutes (4 × 30-, 3 × 60-and 7 × 300-second frames). The PET study protocols are described in more detail in previous reports 13, 17 ( Figure S1A ).
18
F-FDG was synthesized using computer-controlled apparatus. 19 All data were corrected for dead time, decay and measured photon attenuation, and reconstructed using a Hann filter with a cut-off frequency of 0.5 and a median root prior reconstruction method. 20 Arterialized blood samples were drawn during the scan and analysed for radioactivity concentration in plasma using an automatic γ counter (Wizard 1480;
Wallac, Turku, Finland). During the clamp, plasma glucose, serum insulin and free fatty acids were taken at baseline and every 5, 30 and 60 minutes, respectively.
| Quantification of brain glucose metabolism
The influx constant (Ki) was calculated for each voxel separately using the linear Gjedde-Patlak plot with the arterial plasma input function, with a linear phase start time of 20 minutes. BGU (μmol/100 g/min) was then calculated at voxel level as follows:
where Cp is the average plasma glucose concentration from the injection until the end of the brain scan, and LC is the lumped constant for the brain (which was set at 0.65). 21 Brain density was set at 1.04.
22
Summed PET images were spatially normalized to the 
| Calculations
The EGP values and insulin-stimulated glucose disposal (M-values) were calculated as previously described. 15, 23 Briefly, EGP during the euglycae- 3 | RESULTS
| Before surgery
Obese participants had higher glucose and lipid profiles, and higher hepatic enzymes as compared with lean controls. IL-6, high-sensitivity C-reactive protein (hsCRP) and leptin levels were higher in the obese participants as compared to the age-matched lean controls (Table 1 ).
In the overnight fasted state, BGU was not different between obese and lean participants. 13 EGP was higher in the obese as compared with the lean participants when expressed in μmol/min (Table 1) . During the clamp, plasma glucose levels were stable and similar between obese participants and controls throughout the study ( Figure S1B ). Although the exogenous insulin infusion was adjusted for body surface area, steady-state plasma insulin levels were higher in obese participants as a result of lower insulin clearance ( Figure S1C and Table 1 ). As expected, obese participants had lower M-values and higher insulin-suppressed EGP, the two variables being reciprocally related in the whole dataset ( Figures S1D-F) . Insulin-stimulated BGU was~10% higher in obese as compared to control participants ( Figure 1A,D) . 13 Different plasma insulin levels between groups did not account for the difference in BGU. In the whole dataset, insulin- and phenylalanine and leucine, remained significant after adjusting for the M-value (r = 0.68, P = 0.01, and r = 0.67, P = 0.01, respectively).
| After surgery
Six months after surgery, the obese participants had lost 11 BMI units (~24% of their initial body weight), but their BMI remained significantly higher as compared with the controls. The M-value doubled, Abbreviations: AFOS, alkaline phosphatase; ALT, alanine transaminase; BMI, body mass index; EGP, endogenous glucose production; FFM, fat free mass; gGT, gamma-glutamyltransferase; HbA1c, glycated haemoglobin; hsCRP, high-sensitivity C-reactive protein; IGT, impaired glucose tolerance; IL, interleukin; NGT, normal glucose tolerance; T2D, type 2 diabetes. Values are mean AE SD or median [interquartile range]. P 1 = P value for the comparison of obese patients pre-surgery versus lean controls; P 2 = P value for the comparison of obese patients pre-versus post-surgery; P 3 = P value for the comparison of obese patients post-surgery versus lean controls.
and serum IL-6 and CRP levels decreased significantly. Fasting EGP decreased significantly, in accordance with previous findings. 28 Insulin-suppressed EGP showed a small, non-significant decrease and was no longer significantly different from the value in controls (Table 1) . BGU was decreased (~5%) but was still higher than in controls ( Figure S2B ,C) and positively associated with EGP (r = 0.56, P = 0.02; Figure 2A ). Interaction analyses showed no effect of surgical procedure on this association, but the limited sample size does not allow an effect to be conclusively ruled out. The reductions in EGP and BGU were not associated. After surgery, BGU was no longer associated with plasma IL-6 and CRP concentrations.
| Follow-up
Patients remained weight-stable at 2 and 3 years of follow-up (median 
| DISCUSSION
The main findings of the present study were that insulin-stimulated BGU was positively associated with EGP in morbidly obese but not in In addition to the present study population, 13 we have reported in two other study cohorts that insulin resistance was positively associated with insulin-stimulated BGU. We showed that insulinstimulated BGU was higher in individuals with impaired glucose tolerance than in lean individuals. 12 More recently the same finding was reported in individuals with inherited insulin resistance as compared with age-matched controls. 
EGP (μmol·kg FFM /min) FIGURE 2 A, Statistical parametric mapping (SPM) images of the association between insulin-stimulated brain glucose uptake (BGU) and insulinsuppressed endogenous glucose production (EGP) in the obese patients postoperatively and the corresponding scatterplot. In the scatterplot the mean BGU from the significant voxels only is presented (BGU*). B, SPM images of the association between insulin-stimulated BGU at baseline and plasma C-reactive protein (CRP) and the corresponding scatterplot; grey circles: obese (n = 19), white squares: lean controls (n = 7). C, SPM images of the association between insulin-stimulated BGU at baseline and change in plasma glucose at 2 years of follow-up in 17 obese patients and the corresponding scatterplot. P values <0.05 cluster level; FDR-corrected. Higher T values denote stronger associations (coloured bar at the bottom) association between insulin-stimulated BGU and EGP in morbidly obese participants before and after bariatric surgery may help explain why the addition of intranasal insulin to systemic hyperinsulinaemia failed to suppress EGP in the overweight as compared to the lean participants in that study. Notably, we failed to detect any association between EGP and BGU in the fasting state. Although the reason for the discrepancy in this association between the fasting and insulinstimulated state needs to be further elucidated, our data are in line with a previous study conducted by Gancheva et al. 31 who did not observe any effect of intranasal insulin on suppressing EGP during fasting.
It is known that overfeeding rapidly induces insulin resistance. 32 Our findings in turn suggest that in morbidly obese individuals the severe calorie restriction and marked weight loss that follow the combination of a 4-week very-low-energy diet period and bariatric surgery are not sufficient to disrupt the association between BGU and EGP.
Thus, factors other than high-fat diet and obesity per se might be involved in this interrelation.
One salient finding of the present study was that high insulinstimulated BGU predicted worse fasting glycaemia 2 to 3 years after surgery; this longitudinal association persisted after adjusting for BMI and whole-body insulin sensitivity. Impaired β-cell glucose sensing and decreased whole-body insulin sensitivity are known independent predictors of worse glycaemic control in individuals without diabetes. 33 In morbidly obese individuals with normal glucose tolerance who undergo bariatric surgery fasting plasma glucose levels fall rapidly after surgery. 34 Insulin-stimulated BGU at baseline did not predict worse HbA1c levels or weight gain at 2 or 3 years of follow up, but it was a significant predictor of the metabolic change that is mainly linked with increased EGP, that is, fasting glycaemia; this suggests that the brain-EGP axis may be involved in the deterioration of glucose homeostasis over time. To further test our hypothesis that high insulin-stimulated BGU is a predictor of worse metabolic outcome we also analysed metabolite data. We found a positive correlation between BGU and known predictors of increased risk of T2D, such as the branched-chain amino acid leucine and the aromatic amino acid phenylalanine. 35 These findings are in line with results from the TULIP study, an intervention study with lifestyle modification targeting weight loss. In that study, Tschritter et al. 36 showed that central insulin resistance (assessed by magnetoencephalography) was associated with a smaller decrease in total and visceral adipose tissue and fasting plasma glucose levels and worse adherence to the lifestyle recommendations.
Markers of systemic inflammation were positively associated with insulin-stimulated BGU. Thaler et al. 37 have shown that high-fat diet and obesity are associated with neuroinflammation. In a recent study, Zimmer et al. 38 showed that brain 18 F-FDG uptake in PET studies is driven by astrocytes. This is in accord with what was originally proposed as the astrocyte-neuron lactate shuttle, whereby astrocytes convert glucose into lactate and supply lactate to neurons, 39 but this metabolic paradigm remains controversial. 40 Altogether, a plausible interpretation of our data could be that the increased BGU in obesity 13 is, at least in part, attributable to obesity-induced astrocyte pro-
liferation. An obesity-induced astrocyte proliferation could also explain an interplay between brain and EGP. 41 Future PET studies with specific astrocyte ligands are necessary to confirm whether astrocyte proliferation occurs in human obesity.
The present study has some limitations. First, the number of participants was small and, because of the complexity of the study design, we had a relatively large dropout rate. Despite the fact that the postoperative group was smaller, however, the association between BGU and EGP remained significant. Second, it would be interesting to know whether the increased BGU during insulin stimulation affects neuronal functionality, which the present study was not designed to evaluate. Third, it would be interesting to assess small brain areas, such as the hypothalamus, but the spatial resolution of the PET (6-8 mm) does not allow this. 42 Finally, the present study documents associations but does not explain the mechanisms underlying the relationship between BGU and EGP.
In summary, insulin-stimulated BGU in obese individuals is increased as compared to lean individuals, and is positively associated with EGP, markers of systemic inflammation, and levels of branchedchain and aromatic amino acids. Additional studies are needed to unravel the peculiar characteristics of brain insulin resistance, and to elucidate whether the increased BGU in insulin resistance might contribute to further deterioration of glucose homeostasis.
